Form 4: Tenaya Therapeutics Insiders Sell Over 800K Shares

Multiple entities and individuals associated with The Column Group, including directors, have reported the sale of over 800,000 shares of Tenaya Therapeutics common stock in late February 2026.

Summary

• The Column Group III GP, LP, along with related entities and managing partners Peter Svennilson and Tim Kutzkey, reported sales of Tenaya Therapeutics, Inc. common stock.
• A total of 829,734 shares were sold across four separate transactions on February 20, 2026, and February 23, 2026.
• On February 20, 2026, 245,965 shares were sold at a weighted average price of $0.6149 per share, with prices ranging from $0.60 to $0.63.
• Also on February 20, 2026, an additional 277,769 shares were sold at a weighted average price of $0.6149 per share, within the same price range.
• On February 23, 2026, 143,709 shares were sold at a weighted average price of $0.5972 per share, with prices ranging from $0.573 to $0.6225.
• Another 162,291 shares were sold on February 23, 2026, at a weighted average price of $0.5972 per share, within the same price range.
• Following these transactions, The Column Group III, LP indirectly holds 1,958,509 shares and 2,102,218 shares, while The Column Group III-A, LP indirectly holds 2,211,757 shares and 2,374,048 shares.
• TCG Opportunity III LP continues to indirectly hold 49,313,559 shares, which were not part of these reported transactions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the substantial insider selling by a major institutional investor and directors, which often indicates a lack of conviction in the company's short-to-medium term prospects.

Negatives

• Significant insider selling by a 10% owner and directors could signal a lack of confidence in the company's near-term prospects or valuation.
• The sales occurred at relatively low price points, with weighted average prices of $0.6149 and $0.5972, which might suggest a belief that the stock is unlikely to appreciate significantly in the short term.

Risks

• The reported insider sales could lead to negative market sentiment and downward pressure on Tenaya Therapeutics' stock price.
• A large block of shares being sold by a major institutional investor and directors might indicate concerns about future performance or dilution, even if not explicitly stated.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, particularly by significant institutional investors and directors, can sometimes precede periods of underperformance for a company's stock. In the biotechnology sector, such sales might be interpreted as a signal regarding upcoming clinical trial results, regulatory hurdles, or financing needs, although this filing provides no explicit reasons for the sales.

Related Party Transactions

• The reported transactions involve sales of common stock by entities and individuals (The Column Group III GP, LP, The Column Group III, LP, The Column Group III-A, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Tim Kutzkey, and Peter Svennilson) who are identified as directors and/or 10% owners of Tenaya Therapeutics, Inc., making these related party transactions.

Stakeholder Impact

• Shareholders may perceive these sales as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• The company's reputation among investors could be affected if the market interprets these sales as a lack of belief in future growth by key insiders.

Key Dates

Recommendation

The significant insider selling by a 10% owner and directors, totaling over 800,000 shares, suggests a lack of confidence from individuals with privileged information about Tenaya Therapeutics. While the reasons for selling are not disclosed, such large-scale divestment by key stakeholders often precedes periods of stock underperformance. This action signals potential headwinds or a belief that the current valuation is not sustainable, warranting a 'sell' recommendation for seasoned investors.

Keywords

Tenaya Therapeutics, TNYA, SEC Form 4, Insider Selling, The Column Group, Stock Sale, Beneficial Ownership, Director Sales, 10% Owner